AVTX Stock Price History and Quote Analysis: Insights for Investors
Avalo Therapeutics, Inc.
Stock Price Today
Avalo Therapeutics, Inc. (AVTX) stock declined over -2.01%, trading at $9.63 on NASDAQ, down from the previous close of $9.83. The stock opened at $9.67, fluctuating between $9.21 and $10.04 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Company Information
| Employees | 19 |
| Beta | 1.073 |
| Sales or Revenue | $1.92M |
| 5Y Sales Change% | -0.995% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Avalo Therapeutics, Inc. (NASDAQ: AVTX) stock price is $9.63 in the last trading session. During the trading session, AVTX stock reached the peak price of $10.04 while $9.21 was the lowest point it dropped to. The percentage change in AVTX stock occurred in the recent session was -2.01% while the dollar amount for the price change in AVTX stock was -$0.20.
The NASDAQ listed AVTX is part of Biotechnology industry that operates in the broader Healthcare sector. Avalo Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Blake M. Paterson M.D.
Scientific Advisor
Dr. Lisa Hegg Ph.D.
Senior Vice President of Program Management & Corporation Infrastructure
Dr. Dino C. Miano Ph.D.
Senior Vice President of CMC & Technical Operations
Dr. Stephen Thomas Ph.D.
Vice President & Head of Discovery
Dr. Solomon H. Snyder M.D.
Founder and Chairman of Scientific Advisory Board
Ms. Colleen Matkowski
Senior Vice President of Global Regulatory Affairs & Quality Assurance
Dr. Garry A. Neil M.D.
Chairman, Pres & Chief Executive Officer
Mr. Christopher Ryan Sullivan
Chief Financial Officer & Head of Investor relations
Dr. Barbara S. Slusher Ph.D.
Founder and Member of Scientific Advisory Board
AVTX's closing price is 147.29% higher than its 52-week low of $3.95 where as its distance from 52-week high of $45.12 is -78.35%.
Number of AVTX employees currently stands at 19.
Official Website of AVTX is: https://www.avalotx.com
AVTX could be contacted at phone 410 522 8707 and can also be accessed through its website. AVTX operates from 540 Gaither Road, Rockville, MD 20850, United States.
AVTX stock volume for the day was 26.68K shares. The average number of AVTX shares traded daily for last 3 months was 17.15K.
The market value of AVTX currently stands at $93.44M with its latest stock price at $9.63 and 9.7M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com